Back to search

Japan· JP-7290418D1028

ガリウム(68Ga)ゴゼトチド

A medicinal product containing ガリウム(68ga)ゴゼトチド, registered in Japan by ノバルティス ファーマ, on the national reimbursement list.

On Japan’s NHI price list

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedガリウム(68Ga)ゴゼトチドATC—REGISTER NO.JP-7290418D1028PACKS LISTED0CHECKEDOctober 2, 2026

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ガリウム(68Ga)ゴゼトチド
Manufacturer
ノバルティス ファーマ
Country
Japan (JP)
ATC code
—
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
October 2, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

ガリウム(68ga)ゴゼトチド in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ガリウム(68ga)ゴゼトチド products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/60d23fb3-811f-47d9-bc85-b46ab361fada
GET /v1/drugs/60d23fb3-811f-47d9-bc85-b46ab361fada?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "1回分",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "7290418D1028",
  "category": "注射薬",
  "price_yen": 185947,
  "generic_name": "ガリウム(68Ga)ゴゼトチド",
  "product_name_jp": null,
  "therapeutic_class": "7290",
  "transitional_expiry": null
}

See everything about ガリウム(68ga)ゴゼトチド.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.